: The prognosis of patients with advanced cutaneous melanoma has radically changed in the past decade. Nevertheless, primary or acquired resistance to systemic treatment occurs in many cases, highlighting the need for novel treatment strategies. This review has the purpose of summarizing the current area of interest for the treatment of metastatic or unresectable advanced cutaneous melanoma, including data from recently completed or ongoing clinical trials. The main fields of investigation include the identification of new immune checkpoint inhibitors (anti-LAG3, GITR agonist and anti-TIGIT), adoptive cell therapy, vaccines, engineered TCR therapy, IL-2 agonists, novel targets for targeted therapy (new MEK or RAF inhibitors, HDAC, IDO, ERK, Axl, ATR and PARP inhibitors), or combination strategies (antiangiogenetic agents plus immune checkpoint inhibitors, intra-tumoral immunotherapy in combination with systemic therapy). In many cases, only preliminary efficacy data from early phase trials are available, which require confirmation in larger patient cohorts. A more in-depth knowledge of the biological effects of the molecules and identifying predictive biomarkers remain crucial for selecting patient populations most likely to benefit from novel emerging treatment strategies.

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma / Comito, Francesca; Pagani, Rachele; Grilli, Giada; Sperandi, Francesca; Ardizzoni, Andrea; Melotti, Barbara. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 14:2(2022), pp. 1-24. [10.3390/cancers14020271]

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

Comito, Francesca;Pagani, Rachele;Grilli, Giada;Ardizzoni, Andrea;
2022

Abstract

: The prognosis of patients with advanced cutaneous melanoma has radically changed in the past decade. Nevertheless, primary or acquired resistance to systemic treatment occurs in many cases, highlighting the need for novel treatment strategies. This review has the purpose of summarizing the current area of interest for the treatment of metastatic or unresectable advanced cutaneous melanoma, including data from recently completed or ongoing clinical trials. The main fields of investigation include the identification of new immune checkpoint inhibitors (anti-LAG3, GITR agonist and anti-TIGIT), adoptive cell therapy, vaccines, engineered TCR therapy, IL-2 agonists, novel targets for targeted therapy (new MEK or RAF inhibitors, HDAC, IDO, ERK, Axl, ATR and PARP inhibitors), or combination strategies (antiangiogenetic agents plus immune checkpoint inhibitors, intra-tumoral immunotherapy in combination with systemic therapy). In many cases, only preliminary efficacy data from early phase trials are available, which require confirmation in larger patient cohorts. A more in-depth knowledge of the biological effects of the molecules and identifying predictive biomarkers remain crucial for selecting patient populations most likely to benefit from novel emerging treatment strategies.
2022
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma / Comito, Francesca; Pagani, Rachele; Grilli, Giada; Sperandi, Francesca; Ardizzoni, Andrea; Melotti, Barbara. - In: CANCERS. - ISSN 2072-6694. - ELETTRONICO. - 14:2(2022), pp. 1-24. [10.3390/cancers14020271]
Comito, Francesca; Pagani, Rachele; Grilli, Giada; Sperandi, Francesca; Ardizzoni, Andrea; Melotti, Barbara
File in questo prodotto:
File Dimensione Formato  
cancers-14-00271-v2.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.85 MB
Formato Adobe PDF
1.85 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/851933
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact